Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) Short Interest Up 254.8% in March

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) saw a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 51,800 shares, a growth of 254.8% from the February 28th total of 14,600 shares. Currently, 0.0% of the company’s shares are short sold. Based on an average daily trading volume, of 85,100 shares, the days-to-cover ratio is presently 0.6 days.

Fresenius SE & Co. KGaA Trading Up 0.5 %

OTCMKTS FSNUY traded up $0.05 on Friday, reaching $10.92. The company had a trading volume of 19,577 shares, compared to its average volume of 53,583. The firm has a market cap of $24.40 billion, a price-to-earnings ratio of 52.00 and a beta of 1.02. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.36 and a quick ratio of 1.05. Fresenius SE & Co. KGaA has a fifty-two week low of $6.57 and a fifty-two week high of $11.23. The business has a 50 day moving average of $10.13 and a two-hundred day moving average of $9.44.

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) last issued its quarterly earnings results on Wednesday, February 26th. The company reported $0.18 earnings per share for the quarter. The company had revenue of $6.01 billion during the quarter. Analysts forecast that Fresenius SE & Co. KGaA will post 0.79 EPS for the current year.

Analyst Ratings Changes

Separately, Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Fresenius SE & Co. KGaA in a report on Monday, February 3rd.

Fresenius SE & Co. KGaA Company Profile

Fresenius SE & Co KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.